drugset
drugset / Trial / NCT06067490

A Phase I Study of RC1416 Injection

NCT06067490 ↗

Phase 1 Completed 48 enrolled Nanjing RegeneCore Biotech Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.

Timeline

Start
2023-06-29
Primary completion
2024-05-14
Completion
2024-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject RC1416 Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.